|
|
|
|
|
Click Here to return To Results
|
|
|
|
The nature of antibody, and to a lesser extent the clinical syndrome, determines the risk and type of an underlying malignancy. For screening of the thoracic region, a CT-thorax is recommended, which if negative is followed by fluorodeoxyglucose-positron emission tomography (FDG-PET). Breast cancer is screened for by mammography, followed by MRI. For the pelvic region, ultrasound (US) is the investigation of first choice followed by CT. Dermatomyositis patients should have CT-thorax/abdomen, US of the pelvic region and mammography in women, US of testes in men under 50 years and colonoscopy in men and women over 50. If primary, screening is negative, repeat screening after 3-6 months and screen every 6 months up till 4 years. In LEMS, screening for 2 years is sufficient. In syndromes where only subgroup of patients have a malignancy, tumour markers have additional value to predict a probable malignancy. |
|
(click to filter results - removes previous filter)
carcinoma
CAT scan,abdomen
CAT scan,chest
CAT scan,emission
CAT scan,pelvis
encephalitis,paraneoplastic
limbic encephalitis
lymphoma
malignancy screen
mammogram
MRI
MRI,abnormal
MRI,whole body
neurologic complications of,systemic cancer
prognosis
remote effect of cancer on the nervous system
screening
ultrasonography
ultrasonography,pelvis
ultrasonography,testes
whole body imaging
|
Click Here to return To Results
|
|